Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies

Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies

Background: Blood-based tumor mutational burden (bTMB) was recently found to be suboptimal in predicting overall survival (OS) benefits of atezolizumab over docetaxel among patients with advanced non-small cell lung cancer (NSCLC). The maximum somatic allele frequency (MSAF) is an indicator of the p...

Full description

Bibliographic Details
Main Authors: Yu-tong Chen, Sharvesh Raj Seeruttun, Xiang-yuan Wu, Zi-xian Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Oncology
Subjects:
maximum somatic allele frequency (MSAF)
blood-based tumor mutational burden (bTMB)
atezolizumab
docetaxel
non-small cell lung cancer (NSCLC)
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01432/full

Similar Items

Similar Items